Overview
How GLP-1 medications work, what to expect, and what the research shows.
Guide
Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo
There are now three GLP-1 pills in the US, and they aren't interchangeable: oral semaglutide for diabetes (Rybelsus, now sold as Ozempic tablets), oral semaglutide for weight (the Wegovy pill), and orforglipron (Foundayo). Here's how they compare on approval, how you take them, what the trials found, side effects, cost, and what you give up versus a weekly injection.
Guide
Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found
STEP 1, SURMOUNT-4, SELECT, LEADER: GLP-1 trial names get quoted everywhere, usually without context. This reference page lists 205 named, completed GLP-1 trials in one place, grouped by drug and by question, with what each one tested, who sponsored it, its headline result, and a link to the published paper. It also lists the trials that finished but have not reported, and shows who paid for the research.
Guide
A new pancreas study on GLP-1 drugs: what it actually shows
A March 2026 Salk Institute study found a molecular switch, phosphorylation of a protein called Med14, that helps pancreatic beta cells carry out a broad gene response to prolonged GLP-1 exposure. It's a peer-reviewed finding from rat cells and mouse islets, with no human confirmation yet. What it found, what it means, and what it doesn't tell us.
Guide
Obesity phenotypes: why "hungry gut" vs "hungry brain" may change your GLP-1 results
Researchers now describe four "phenotypes" of obesity (hungry brain, hungry gut, emotional hunger, and slow burn), and early evidence suggests they help explain why the same GLP-1 produces very different results in different people. One newly described "hungry gut" subtype lost nearly twice as much weight on tirzepatide. What the phenotypes are, what the studies show, and what to know before paying for a phenotype test.
Guide
What the ADA guidelines say about GLP-1 medications — and what changed for type 1 diabetes in 2026
The American Diabetes Association's Standards of Care is the reference most US clinicians follow, and it now puts GLP-1 medications at the center of treating diabetes with obesity. It names GLP-1s as the preferred obesity medication in type 2 diabetes, sets realistic weight-loss targets, and says the highest dose isn't always the goal. The headline 2026 change: for the first time, the ADA cautiously supports GLP-1 therapy for people with type 1 diabetes and obesity, with important safety guardrails.
Guide
GLP-1 super-responders (and non-responders): why weight loss varies so much
On the same drug at the same dose, one person loses 25% of their body weight and another loses almost nothing. In the tirzepatide trials, half or more of people on the higher doses lost 20% or more, but a large real-world analysis found only about 1 in 8 lost more than 15% in a year, while nearly half lost under 5%. What predicts a strong response (early weight change, drug choice, sex, diabetes, biology), why real-world results trail the trials, and what to do if you're not responding.
Guide
Do GLP-1 receptors "burn out"? What long-term use actually does
A common worry is that GLP-1 receptors "burn out" with long-term use: that the drug stops working or permanently damages your natural system. Where the idea comes from, what two-year trial data show, which effect really does fade (the slowing of stomach emptying), why a plateau is a new equilibrium, and what happens to your own appetite when you stop.
Guide
Common mistakes people make on GLP-1 medications — and how to avoid them
Most GLP-1 setbacks come from a short list of avoidable mistakes: treating it as a quick fix, neglecting protein and strength training, rushing the dose, under-hydrating, putting up with side effects instead of managing them, and going it alone. This guide covers the common ones, why they matter, and where to find the fix for each.
Guide
What obesity actually is: history, diagnosis, and why medicine calls it a chronic disease
The formula used to diagnose obesity was invented in the 1830s by an astronomer studying populations, not patients, and a lot of what we assume about obesity rests on tools and ideas never designed for the job. How the definition moved from moral failing to medical diagnosis, how it's diagnosed today, why major medical bodies classify it as a disease, why it's considered chronic, and where the stigma comes from.
Guide
Can you boost GLP-1 naturally? How food and lifestyle compare to the medications
You can raise your own GLP-1 with protein, fermentable fiber, and exercise, and that part is real. What doesn't hold up is the implied equivalence with the medications. This guide covers what nudges your natural GLP-1, why your body clears it in minutes while the drugs hold it for a week, and why "natural boosting" works as a foundation for treatment and can't replace it.
Guide
What to realistically expect on a GLP-1
A GLP-1 doesn't work like a switch. Expect weeks of dose titration before much happens, then average loss of roughly 1% of body weight a month in the big trials, wide variation between fast and slow responders, an expected plateau, and a treatment you plan to stay on long term.
Guide
How GLP-1 medications work, in plain language
Semaglutide and tirzepatide copy hormones your gut already makes after a meal. This guide explains what those hormones do, why the medications quiet hunger and 'food noise,' what the second hormone in tirzepatide adds, and how the same signal that cuts appetite can also cause nausea.